Inv16 p13q22 t1616p13q22 Gene Rearrangement Quantitative MRD Monitor Test sale cost 1220 AED
JAK 2 Mutation Detection Qualitative PCR Test sale cost 1240 AED JAK 2 Mutation Detection Qualitative PCR Test Cost 1,380 د.إ Original price was: 1,380 د.إ.1,240 د.إCurrent price is: 1,240 د.إ.
PML RARA t1517q22q12 Gene Rearrangement Quantitative MRD Monitor Test sale cost 1220 AED PML RARA t1517q22q12 Gene Rearrangement Quantitative MRD Monitor Test Cost 1,350 د.إ Original price was: 1,350 د.إ.1,220 د.إCurrent price is: 1,220 د.إ.
Sale!

Inv16 p13q22 t1616p13q22 Gene Rearrangement Quantitative MRD Monitor Test Cost

Original price was: 1,350 د.إ.Current price is: 1,220 د.إ.

-10%

The “Inv16 p13q22 t(16;16)(p13;q22) Gene Rearrangement Quantitative MRD Monitor Test” is a specialized genetic diagnostic tool used in medical laboratories to detect and quantify the presence of a specific chromosomal abnormality associated with certain types of leukemia, particularly acute myeloid leukemia (AML). This chromosomal rearrangement involves the inversion of chromosome 16 or a translocation between chromosomes 16 and 16 at specified locations, which can play a critical role in the development of the disease.

Monitoring minimal residual disease (MRD) through this test allows healthcare providers to assess the effectiveness of treatment, predict relapse, and adjust therapeutic strategies accordingly. The test utilizes advanced molecular techniques to provide precise quantification of the gene rearrangement, offering valuable insights into the patient’s disease status and prognosis.

Performed at DNA Labs UAE, a leading facility in genetic testing, the cost of the Inv16 p13q22 t(16;16)(p13;q22) Gene Rearrangement Quantitative MRD Monitor Test is 1220 AED. The lab is equipped with state-of-the-art technology and staffed by experts in the field of molecular genetics, ensuring accurate and reliable results for patients and their healthcare providers.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Inv16 p13q22 t1616p13q22 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test

At DNA Labs UAE, we offer the Inv16 p13q22 t1616p13q22 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test. This diagnostic test is designed to monitor minimal residual disease (MRD) in patients with genetic rearrangements involving the Inv16 (p13q22) or t(1616)(p13q22) genes.

Test Details

The Inv16 (p13q22) / t(1616)(p13q22) gene rearrangement quantitative MRD monitor test is a diagnostic test used to monitor minimal residual disease (MRD) in patients with certain genetic rearrangements involving the Inv16 (p13q22) or t(1616)(p13q22) genes. MRD refers to the small number of cancer cells that may remain in a patient’s body after treatment, even when there is no evidence of disease.

Monitoring MRD is important in assessing the effectiveness of treatment and predicting the likelihood of relapse. This specific test is designed to detect and quantify the presence of the Inv16 (p13q22) or t(1616)(p13q22) gene rearrangements in a patient’s bone marrow or blood sample. These gene rearrangements are associated with certain types of leukemia, such as acute myeloid leukemia (AML).

The test utilizes a quantitative polymerase chain reaction (qPCR) technique to amplify and quantify the specific gene rearrangements. By measuring the levels of the rearranged genes, the test can provide information about the extent of MRD in a patient’s body. The results of the test can help healthcare providers determine the appropriate treatment plan for the patient. If the MRD levels remain high, additional treatments or interventions may be necessary to prevent relapse. Conversely, if the MRD levels are low or undetectable, it indicates a good response to treatment and a lower risk of relapse.

It is important to note that this test is specific to the Inv16 (p13q22) or t(1616)(p13q22) gene rearrangements and may not be applicable to other types of genetic rearrangements or cancers. Additionally, the test should be interpreted by a qualified healthcare professional who is familiar with the specific genetic abnormalities and their implications in the context of the patient’s overall condition.

Test Components and Price

The Inv16 p13q22 t1616p13q22 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test is priced at 1220.0 AED. The test includes a sample condition of 5 mL (3 mL min.) whole blood / Bone marrow in 1 Lavender Top (EDTA) tube. The sample should be shipped refrigerated and should not be frozen. A duly filled MRD Requisition form (Form 22) with historical data is mandatory for the test.

Report Delivery

The sample for the test should be submitted on Monday or Thursday by 11 am, and the report will be delivered on Wednesday or Saturday.

Method

The Inv16 p13q22 t1616p13q22 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test utilizes the Real Time PCR method for accurate results.

Test Type

The test falls under the category of Cancer tests.

Doctor and Test Department

The Inv16 p13q22 t1616p13q22 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test is conducted by Oncologists and Hematologists in the Molecular Diagnostics department.

Pre Test Information

A duly filled MRD Requisition form (Form 22) with historical data is mandatory for the test.

Test Name Inv16 p13q22 t1616p13q22 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test
Components
Price 1220.0 AED
Sample Condition 5 mL (3 mL min.) whole blood \/ Bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled MRD Requisition form (Form 22) with historical data is mandatory.
Report Delivery SampleMon / Thu by 11 am; Report Wed / Sat
Method Real Time PCR
Test type Cancer
Doctor Oncologist, Hematologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Duly filled MRD Requisition form (Form 22) with historical data is mandatory.
Test Details

The Inv16 (p13q22) / t(1616)(p13q22) gene rearrangement quantitative MRD monitor test is a diagnostic test used to monitor minimal residual disease (MRD) in patients with certain genetic rearrangements involving the Inv16 (p13q22) or t(1616)(p13q22) genes.

MRD refers to the small number of cancer cells that may remain in a patient’s body after treatment, even when there is no evidence of disease. Monitoring MRD is important in assessing the effectiveness of treatment and predicting the likelihood of relapse.

This specific test is designed to detect and quantify the presence of the Inv16 (p13q22) or t(1616)(p13q22) gene rearrangements in a patient’s bone marrow or blood sample. These gene rearrangements are associated with certain types of leukemia, such as acute myeloid leukemia (AML).

The test utilizes a quantitative polymerase chain reaction (qPCR) technique to amplify and quantify the specific gene rearrangements. By measuring the levels of the rearranged genes, the test can provide information about the extent of MRD in a patient’s body.

The results of the test can help healthcare providers determine the appropriate treatment plan for the patient. If the MRD levels remain high, additional treatments or interventions may be necessary to prevent relapse. Conversely, if the MRD levels are low or undetectable, it indicates a good response to treatment and a lower risk of relapse.

It is important to note that this test is specific to the Inv16 (p13q22) or t(1616)(p13q22) gene rearrangements and may not be applicable to other types of genetic rearrangements or cancers. Additionally, the test should be interpreted by a qualified healthcare professional who is familiar with the specific genetic abnormalities and their implications in the context of the patient’s overall condition.

SKU: TEST-5636 Category:

Related products